http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Vibrio vulnipcus 에 대한 경구용백신 CJ-50002 의 일반약리작용
박완제(Wan Je Park),김영훈(Young Hoon Kim),정성목(Seong Mok Jeong),이영수(Young Soo Lee),신재규(Jae Kyu Shin),최재묵(Jae Mook Choi),이나경(Na Gyong Lee),이윤하(Youn Ha Lee) 한국응용약물학회 1999 Biomolecules & Therapeutics(구 응용약물학회지) Vol.7 No.1
CJ-50002 is an oral vaccine against V. vulnificus infection composed of whole cell lysate of V. vulnificus. The general pharmacological properties of CJ-50002 were evaluated in various animals and in vitro system. CJ-50002 at oral doses of 0.2, 2 and 20 mg/kg had no effect on general behavior in mice, chemoand electro-convulsions in mice, writhing syndrome induced by acetic acid in mice, body temperature in rats, charcoal meal propulsion in mice and urine and electrolytes excretion in rats. However, oral administration of CJ-50002 at dose of 20 mg/kg prolonged the hexobarbital-inuced sleeping inducing time in mice. In anesthetized dogs, CJ-50002 showed no effect on blood pressure, heart rate and ECG but decreased the respiratory rate and femoral blood flow at dose of 20 mg/kg. p.o. CJ-50002 had no effect on the contractile response of the isolated guinea pig ileum to various spasmogen at concentrations of 0.2, 2 and 20 ㎍/ml, respectively. Since these pharmacological effects of CJ-50002 were observed at dose much greater than those in clinical use (approximately 0.16 mg/kg, p.o.), it is likely that this vaccine may be relatively free of undesirable effects in clinical practice.
강재구(Jae-Ku Kang),이성학(Sung Hak Lee),김달현(Dal Hyun Kim),이나경(Na-Gyong Lee),박완제(Wan Je Park),이영수(Young Soo Lee) 한국독성학회 1999 Toxicological Research Vol.15 No.2
We have been developing a vaccine (CJ-50002) against Vibrio vulnificus, composed of whole cell lysate of a V. vulnificus O-antigen serotype 4-strain. In order to evaluate the mutagenic potential of CJ-50002, 3 sets of mutagenicity tests were performed. In the reverse mutation test using Salmonella typhimurium TA1535, TA1537, TA98 and TA100, CJ-50002 did not increase the number of revertant at any concentration tested in this study (309.6, 154.8, 77.4, 38.7, 19.4 and 9.7 ㎍/plate). CJ-50002, at concentrations of 309.6, 154.8 and 77.4 ㎍/ml, did not increase the number of cells having structural or numerical chromosome aberration in cytogenic test using Chinese Hamster Lung cells. In mouse micronucleus test, no significant increase in the occurrence of micro nucleated polychromatic erythrocytes was observed in ICR male mice orally administered with CJ-50002 at the doses of 500, 250 and 125 mg/kg. These results indicate that CJ-50002 has no mutagenic potential in these in vitro and in vivo systems.
유전자 재조합 B 형 간염 바이러스 표면 항원 , CJC-50100 의 일반약리작용
정성학(Seong Hak Jeong),최재묵(Jae Mook Choi),이남중(Nam Jung Lee),전형수(Hyung Soo Jeon),김연희(Yon Hee Kim),김재승(Jae Seung Kim),하석훈(Suk Hoon Ha),김영훈(Young Hoon Kim),이나경(Na Gyung Lee),김제학(Je Hak Kim),박완제(Wan Je Park 한국응용약물학회 2001 Biomolecules & Therapeutics(구 응용약물학회지) Vol.9 No.1
N/A CJC-50100 is a recombinant hepatitis B virus surface antigen (HBsAg) expressed in yeast. The general pharmacological properties of CJC-50100 were evaluated in mice, rats, dogs and isolated guinea pig ileum. The doses were 0.33∼33.3 ㎍/㎏ i.m. for mice and rats and 3.3∼9.9 ㎍/㎏ i.v. for dogs. The concentrations of 0.002∼0.02 ㎍/mlwere used for the assay with guinea pig ileum. Intramuscular administration of CJC-50100 at the doses did not alter general behavior and the responses for central nervous system, smooth muscle, gastrointestinal system, cardiovascular and respiratory system, and water and electrolytes excretion. In summary, CJC-50100 had no pharmacological effect in these studies even up to the 100-fold of the expected clinical dose, 20 ㎍/man/60 kg.